The key finding of this study was that m6A regulator METTL3 was associated with tumor HPV status and HPV expression, and METTL3 high status facilitated the formation of an immunosuppressed tumor microenvironment and targeting METTL3 promoted immunotherapy in HPV-related cervical cancer. Here, METTL3 is linked to cervical carcinoma.